Back to Search
Start Over
Neuroprotective potential of topiramate, pregabalin and lacosamide combination in a rat model of acute SE and intractable epilepsy: Perspectives from electroencephalographic, neurobehavioral and regional degenerative analysis.
- Source :
-
European journal of pharmacology [Eur J Pharmacol] 2024 Sep 05; Vol. 978, pp. 176792. Date of Electronic Publication: 2024 Jun 29. - Publication Year :
- 2024
-
Abstract
- The lithium-pilocarpine model is commonly used to recapitulate characteristics of human intractable focal epilepsy. In the current study, we explored the impact of topiramate (TPM) alone and in combination with pregabalin and lacosamide administration for 6 weeks on the evolution of spontaneous recurrent seizures (SRS) and disease-modifying potential on associated neuropsychiatric comorbidities. In addition, redox impairments and neurodegeneration in hippocampus regions vulnerable to temporal lobe epilepsy (TLE) were assessed by cresyl violet staining. Results revealed that acute electrophysiological (EEG) profiling of the ASD cocktail markedly halted sharp ictogenic spikes as well as altered dynamics of brain wave oscillations thus validating the need for polytherapy vs. monotherapy. In TLE animals, pharmacological intervention for 6 weeks with topiramate 10 mg/kg in combination with PREG and LAC at the dose of 20 mg/kg exhibited marked protection from SRS incidence, improved body weight, offensive aggression, anxiety-like behavior, cognitive impairments, and depressive-like behavior (p < 0.05). Moreover, combination therapy impeded redox impairments as evidenced by decreased MDA and AchE levels and increased activity of antioxidant SOD, GSH enzymes. Furthermore, polytherapy rescued animals from SE-induced neurodegeneration with increased neuronal density in CA1, CA3c, CA3ab, hilus, and granular cell layer (GCL) of the dentate gyrus. In conclusion, early polytherapy with topiramate in combination with pregabalin and lacosamide prompted synergy and prevented epileptogenesis with associated psychological and neuropathologic alterations.<br />Competing Interests: Declaration of competing interest The authors indicated no potential conflicts of interest.<br /> (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Subjects :
- Animals
Male
Rats
Behavior, Animal drug effects
Drug Resistant Epilepsy drug therapy
Drug Therapy, Combination
Hippocampus drug effects
Hippocampus physiopathology
Hippocampus pathology
Anticonvulsants pharmacology
Anticonvulsants therapeutic use
Status Epilepticus drug therapy
Status Epilepticus chemically induced
Status Epilepticus physiopathology
Rats, Wistar
Epilepsy, Temporal Lobe drug therapy
Epilepsy, Temporal Lobe physiopathology
Epilepsy, Temporal Lobe chemically induced
Lacosamide pharmacology
Lacosamide therapeutic use
Topiramate pharmacology
Topiramate therapeutic use
Neuroprotective Agents pharmacology
Neuroprotective Agents therapeutic use
Pregabalin pharmacology
Pregabalin therapeutic use
Disease Models, Animal
Electroencephalography
Subjects
Details
- Language :
- English
- ISSN :
- 1879-0712
- Volume :
- 978
- Database :
- MEDLINE
- Journal :
- European journal of pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 38950834
- Full Text :
- https://doi.org/10.1016/j.ejphar.2024.176792